Trials (Jul 2024)

The efficacy of simple oral nutritional supplements versus usual care in postoperative patients with gastric cancer: study protocol for a multicenter, open-label, parallel, randomized controlled trial

  • Kohei Ueno,
  • Tatsuto Nishigori,
  • Yukinari Tokoro,
  • Akiyoshi Nakakura,
  • Shigeru Tsunoda,
  • Shigeo Hisamori,
  • Kyoichi Hashimoto,
  • Seiichiro Kanaya,
  • Kenjiro Hirai,
  • Eiji Tanaka,
  • Hiroaki Hata,
  • Dai Manaka,
  • Masazumi Sakaguchi,
  • Masato Kondo,
  • Takatsugu Kan,
  • Atsushi Itami,
  • Akira Miki,
  • Yuichiro Kawamura,
  • Kosuke Toda,
  • Hiroshi Okabe,
  • Michihiro Yamamoto,
  • Yoshito Yamashita,
  • Yosuke Kinjo,
  • Hironori Kawada,
  • Kazutaka Obama,
  • Kyoto Esophageal, Gastric Cancer Surgery Group (KEGG)

DOI
https://doi.org/10.1186/s13063-024-08169-8
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Body weight loss (BWL) after gastrectomy impact on the short- and long-term outcomes. Oral nutritional supplement (ONS) has potential to prevent BWL in patients after gastrectomy. However, there is no consistent evidence supporting the beneficial effects of ONS on BWL, muscle strength and health-related quality of life (HRQoL). This study aimed to evaluate the effects of ONS formulated primarily with carbohydrate and protein on BWL, muscle strength, and HRQoL. Methods This will be a multicenter, open-label, parallel, randomized controlled trial in patients with gastric cancer who will undergo gastrectomy. A total of 120 patients who will undergo gastrectomy will be randomly assigned to the ONS group or usual care (control) group in a 1:1 ratio. The stratification factors will be the clinical stage (I or ≥ II) and surgical procedures (total gastrectomy or other procedure). In the ONS group, the patients will receive 400 kcal (400 ml)/day of ONS from postoperative day 5 to 7, and the intervention will continue postoperatively for 8 weeks. The control group patients will be given a regular diet. The primary outcome will be the percentage of BWL (%BWL) from baseline to 8 weeks postoperatively. The secondary outcomes will be muscle strength (handgrip strength), HRQoL (EORTC QLQ-C30, QLQ-OG25, EQ-5D-5L), nutritional status (hemoglobin, lymphocyte count, albumin), and dietary intake. All analyses will be performed on an intention-to-treat basis. Discussion This study will provide evidence showing whether or not ONS with simple nutritional ingredients can improve patient adherence and HRQoL by reducing BWL after gastrectomy. If supported by the study results, nutritional support with simple nutrients will be recommended to patients after gastrectomy for gastric cancer. Trial registration jRCTs051230012; Japan Registry of Clinical Trails. Registered on Apr. 13, 2023.

Keywords